{"id":471,"date":"2023-02-20T16:39:52","date_gmt":"2023-02-20T15:39:52","guid":{"rendered":"https:\/\/www.chu-tours.fr\/pemr-cvl\/?page_id=471"},"modified":"2024-02-20T11:33:28","modified_gmt":"2024-02-20T10:33:28","slug":"sclerose-laterale-amyotrophique-et-autres-maladies-rares-du-neurone-moteur","status":"publish","type":"page","link":"https:\/\/www.chu-tours.fr\/pemr-cvl\/sclerose-laterale-amyotrophique-et-autres-maladies-rares-du-neurone-moteur\/","title":{"rendered":"Scl\u00e9rose Lat\u00e9rale Amyotrophique et autres Maladies Rares du Neurone Moteur"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"471\" class=\"elementor elementor-471\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ab32dc0 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ab32dc0\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-68e0dc0e\" data-id=\"68e0dc0e\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-68e93f27 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"68e93f27\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-6f89607a\" data-id=\"6f89607a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-4def3c2a\" data-id=\"4def3c2a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-73e39d94 elementor-widget elementor-widget-image\" data-id=\"73e39d94\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 15-07-2024 *\/\n.elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=\".svg\"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block}<\/style>\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.arsla.org\" target=\"_blank\">\n\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"300\" height=\"194\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/logo-arsla-35ans.jpg\" class=\"attachment-medium size-medium wp-image-475\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-ee88e05\" data-id=\"ee88e05\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-3bcdd322 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"3bcdd322\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-63eb1d21\" data-id=\"63eb1d21\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1d01a94c elementor-widget elementor-widget-text-editor\" data-id=\"1d01a94c\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 15-07-2024 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p><span style=\"font-size: 14pt;color: #ed1164\">Face \u00e0 l\u2019\u00e9pid\u00e9mie de coronavirus qui touche la France, les \u00e9quipes de l\u2019ARSLA restent op\u00e9rationnelles pour prot\u00e9ger les malades, les aidants et les informer !<\/span><\/p><p>L\u2019\u00e9pid\u00e9mie de COVID-19 actuellement en cours en France impose aux personnes fragiles d\u2019\u00eatre particuli\u00e8rement vigilantes et de prendre de fortes pr\u00e9cautions pour \u00e9viter tout risque de contamination. L&#8217;ARSLA reste mobilis\u00e9e pour vous accompagner et vous guider au mieux.<\/p><p>Un <strong>dispositif sp\u00e9cifique<\/strong> a \u00e9t\u00e9 mis en place :<\/p><ul><li>Une permanence t\u00e9l\u00e9phonique ouverte 7\/7 de 9h30 \u00e0 18h30 au 01 58 30 58 57<\/li><li>Des groupes de parole en ligne pour les aidants (s\u00e9curis\u00e9). Le prochain groupe est pr\u00e9vu jeudi 9 avril \u00e0 14h. Inscription obligatoire : <a href=\"mailto:contact@arsla.org\">contact@arsla.org<\/a><\/li><li>Des <strong>ateliers de cuisine MIXITON<\/strong> en ligne \u00e0 l&#8217;approche de P\u00e2ques afin de\u00a0 partager en famille un m\u00eame et seul repas &#8211; Rendez-vous le vendredi 10 avril \u00e0 14h 30 &#8211; Inscription obligatoire :\u00a0<a href=\"mailto:contact@arsla.org\">contact@arsla.org<\/a><\/li><li>Des <strong>facebooklive<\/strong> tous les vendredis \u00e0 14h pour r\u00e9pondre en direct aux questions de nos internautes : rendez-vous sur l&#8217;une de nos pages facebbok\u00a0 #ARSLA ou #Ensemble parlons de la SLA<\/li><li>Mise en ligne d&#8217;une <strong>FAQ sp\u00e9ciale COVID <\/strong>mise \u00e0 jour r\u00e9guli\u00e8rement : soins, aides \u00e0 domicile, rendez-vous m\u00e9dicaux, on fait le point sur l\u2019ensemble des recommandations \u00e0 suivre si vous \u00eates une personne concern\u00e9e par la SLA ou un proche.<\/li><li>Pr\u00eat d&#8217;aides techniques, conseil en ergoth\u00e9rapie : vous pouvez joindre nos ergoth\u00e9rapeutes du lundi au vendredi de 10h \u00e0 17h au 01 58 30 58 52\/53.<\/li><\/ul>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6df7c726 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6df7c726\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7d155ee5\" data-id=\"7d155ee5\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2226ef1c elementor-widget elementor-widget-heading\" data-id=\"2226ef1c\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 15-07-2024 *\/\n.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}<\/style><h2 class=\"elementor-heading-title elementor-size-default\">Centre de R\u00e9f\u00e9rence Coordonnateur National sur la Scl\u00e9rose Lat\u00e9rale Amyotrophique et autres Maladies Rares du Neurone Moteur<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-64617381 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"64617381\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-6bb1d9f5\" data-id=\"6bb1d9f5\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4e2a8fda elementor-widget elementor-widget-image\" data-id=\"4e2a8fda\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"131\" height=\"101\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/logo-crmr.png\" class=\"attachment-medium size-medium wp-image-361\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-12f1d070\" data-id=\"12f1d070\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-61d35904\" data-id=\"61d35904\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-21865003 elementor-widget elementor-widget-image\" data-id=\"21865003\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"160\" height=\"106\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/logo-filslan.png\" class=\"attachment-medium size-medium wp-image-476\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-3aba0554 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"3aba0554\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2e4f55f7\" data-id=\"2e4f55f7\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-58df3097 elementor-widget elementor-widget-text-editor\" data-id=\"58df3097\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p><strong>Le Centre de r\u00e9f\u00e9rence coordonnateur national est compos\u00e9 d\u2019une \u00e9quipe multidisciplinaire sp\u00e9cialis\u00e9e dans la prise en charge de la Scl\u00e9rose Lat\u00e9rale Amyotrophique et des autres Maladies Rares du Neurone Moteur. <\/strong>.<\/p><p>Ses missions :<\/p><ul><li>Assurer le diagnostic et la coordination des soins, ainsi que l\u2019accompagnement lors de la phase terminale de la maladie<\/li><li>Coordonner et participer \u00e0 des projets de\u00a0 recherche (fondamentales, cliniques, \u00e9pid\u00e9miologiques)<\/li><li>Promouvoir l\u2019enseignement et la formation<\/li><\/ul><p>Le centre est membre:<\/p><ul><li>De la Fili\u00e8re de Sant\u00e9 Maladies Rares FILSLAN<\/li><li>Du groupe europ\u00e9en ENCALS et TRICALS<\/li><\/ul>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-1fc1e39e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"1fc1e39e\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-1d5897e7\" data-id=\"1d5897e7\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-44e9669d elementor-widget elementor-widget-image\" data-id=\"44e9669d\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"40\" height=\"40\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/uk-flag-square-icon-128-40x40-1-40x40.png\" class=\"attachment-pictogramme-home size-pictogramme-home wp-image-372\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-53eb4d6a\" data-id=\"53eb4d6a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-460165c elementor-widget elementor-widget-toggle\" data-id=\"460165c\" data-element_type=\"widget\" data-widget_type=\"toggle.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 15-07-2024 *\/\n.elementor-toggle{text-align:start}.elementor-toggle .elementor-tab-title{font-weight:700;line-height:1;margin:0;padding:15px;border-bottom:1px solid #d5d8dc;cursor:pointer;outline:none}.elementor-toggle .elementor-tab-title .elementor-toggle-icon{display:inline-block;width:1em}.elementor-toggle .elementor-tab-title .elementor-toggle-icon svg{margin-inline-start:-5px;width:1em;height:1em}.elementor-toggle .elementor-tab-title .elementor-toggle-icon.elementor-toggle-icon-right{float:right;text-align:right}.elementor-toggle .elementor-tab-title .elementor-toggle-icon.elementor-toggle-icon-left{float:left;text-align:left}.elementor-toggle .elementor-tab-title .elementor-toggle-icon .elementor-toggle-icon-closed{display:block}.elementor-toggle .elementor-tab-title .elementor-toggle-icon .elementor-toggle-icon-opened{display:none}.elementor-toggle .elementor-tab-title.elementor-active{border-bottom:none}.elementor-toggle .elementor-tab-title.elementor-active .elementor-toggle-icon-closed{display:none}.elementor-toggle .elementor-tab-title.elementor-active .elementor-toggle-icon-opened{display:block}.elementor-toggle .elementor-tab-content{padding:15px;border-bottom:1px solid #d5d8dc;display:none}@media (max-width:767px){.elementor-toggle .elementor-tab-title{padding:12px}.elementor-toggle .elementor-tab-content{padding:12px 10px}}.e-con-inner>.elementor-widget-toggle,.e-con>.elementor-widget-toggle{width:var(--container-widget-width);--flex-grow:var(--container-widget-flex-grow)}<\/style>\t\t<div class=\"elementor-toggle\">\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-7341\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-7341\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><em>The reference centre is composed of a multidisciplinary team specialised in ...<\/em><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-7341\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-7341\"><p><em>The reference centre is composed of a multidisciplinary team specialised in the care of Amytrophic Lateral Sclerosis and Rare Motor-Neuron Diseases.\u00a0 <\/em><\/p><p><em>The duties of the centre are :<\/em><\/p><ul><li><em>Ensure the diagnostic and the coordination of care including providing care and support for the terminally ill<\/em><\/li><li><em>Organise and participate in research projects (fundamental, clinical, epidemiological)<\/em><\/li><li><em>Promote education and training<\/em><\/li><\/ul><p><em>The centre is a member :<\/em><\/p><ul><li><em>Of the French National Rare Disease Network FILSLAN<\/em><\/li><li><em>The European Network for the Cure of ALS (ENCALS)<\/em><\/li><li><em>The European Research Initiative to find a cure for ALS (TRICALS)<\/em><\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2fb206fc elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2fb206fc\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2fe6940d\" data-id=\"2fe6940d\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7fc2e34e elementor-widget elementor-widget-image\" data-id=\"7fc2e34e\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"155\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/sla-pathologies-300x155-1.png\" class=\"attachment-medium size-medium wp-image-477\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">PATHOLOGIES CONCERN\u00c9ES<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5971e77c elementor-widget elementor-widget-toggle\" data-id=\"5971e77c\" data-element_type=\"widget\" data-widget_type=\"toggle.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-toggle\">\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1501\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-1501\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>Pathologies concern\u00e9es<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-1501\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-1501\"><h4>QU&#8217;EST-CE QUE LA SCL\u00c9ROSE LAT\u00c9RALE AMYOTROPHIQUE ?<\/h4><ul><li>La scl\u00e9rose lat\u00e9rale amyotrophique (<strong>SLA<\/strong>) ou<strong> maladie de Charcot<\/strong> est une maladie li\u00e9e \u00e0 l\u2019atteinte des motoneurones dans le cerveau et la moelle \u00e9pini\u00e8re. Les motoneurones commandent le fonctionnement de l\u2019ensemble des muscles squelettiques.<\/li><\/ul><h4>COMBIEN DE PERSONNES SONT ATTEINTES DE CETTE MALADIE ?<\/h4><ul><li>La <strong>SLA<\/strong> affecte aujourd\u2019hui <strong>5 000 \u00e0 7 000 patients<\/strong> contemporains en France, avec une incidence annuelle (nombre de nouveaux cas par an) proche de 2.5 pour 100 000 habitants. On estime que chaque jour, en France, 4 nouveaux cas sont diagnostiqu\u00e9s.<\/li><\/ul><h4>\u00c0 QUOI EST-ELLE DUE ?<\/h4><ul><li>L&#8217;origine de la <strong>SLA<\/strong> est complexe \u00e0 d\u00e9terminer : la survenue de la maladie serait multifactorielle, soumise \u00e0 l&#8217;influence de la g\u00e9n\u00e9tique et de l&#8217;environnement.<\/li><\/ul><h4>QUELLES SONT LES AUTRES MALADIES RARES DU NEURONE MOTEUR?<\/h4><ul><li>La <strong>Maladie du Kennedy<\/strong> ou amyotrophie bulbo-spinale li\u00e9e \u00e0 l\u2019X est une maladie g\u00e9n\u00e9tique caract\u00e9ris\u00e9e par une atrophie musculaire proximale et bulbaire. La pr\u00e9valence de la maladie est de 1\/30.000 naissances masculines avec une incidence annuelle de 1\/526.000. La maladie de Kennedy se d\u00e9clare entre l\u2019\u00e2ge de 30 et 60 ans par un tremblement, des crampes musculaires, des fasciculations, une fatigabilit\u00e9 musculaire et une dysarthrie. Avec la progression de la maladie, d&#8217;autres signes touchant les muscles des membres avec faiblesse et amyotrophie proximale et les muscles bulbaires avec dysarthrie, dysphonie, m\u00e2choire tombante, atrophie de la langue, difficult\u00e9s de mastication et de d\u00e9glutition apparaissent.<\/li><li>La <strong>scl\u00e9rose lat\u00e9rale primitive<\/strong> est li\u00e9e \u00e0 la d\u00e9g\u00e9n\u00e9rescence\u00a0 des motoneurones du cerveau. Elle est plus rare que la <strong>SLA<\/strong> et son \u00e9volution est plus longue.<\/li><li>Plus d\u2019informations sur les maladies rares : <a href=\"https:\/\/www.orpha.net\/consor\/cgi-bin\/index.php?lng=FR\" target=\"_blank\" rel=\"noopener\">https:\/\/www.orpha.net\/consor\/cgi-bin\/index.php?lng=FR<\/a><\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-612a24e6 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"612a24e6\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-57bc1537\" data-id=\"57bc1537\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6c120ba4 elementor-widget elementor-widget-image\" data-id=\"6c120ba4\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/equipe-300x300-1-300x300.png\" class=\"attachment-medium size-medium wp-image-366\" alt=\"\" srcset=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/equipe-300x300-1.png 300w, https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/equipe-300x300-1-150x150.png 150w, https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/equipe-300x300-1-40x40.png 40w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">L'\u00c9QUIPE<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-575138d6 elementor-widget elementor-widget-toggle\" data-id=\"575138d6\" data-element_type=\"widget\" data-widget_type=\"toggle.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-toggle\">\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1461\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-1461\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>L'\u00e9quipe<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-1461\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-1461\"><p><strong>\u00c9quipe m\u00e9dicale\u00a0<\/strong><\/p><ul><li>Pr Philippe CORCIA &#8211; Neurologue &#8211; <strong>M\u00e9decin Coordonnateur du Centre <\/strong><\/li><li>Dr St\u00e9phane BELTRAN &#8211; Neurologue<\/li><li>Dr Anne Sophie PIEGAY &#8211; Neurologue<\/li><li>Dr Delphine CARMIER &#8211; Pneumologue<\/li><\/ul><p><strong>\u00c9quipe param\u00e9dicale<\/strong><\/p><ul><li>Mme Anne FERNANDEZ &#8211; Psychologue<\/li><li>Mme Rosa Maria DOS SANTOS &#8211; Cadre de Sant\u00e9<\/li><li>Mme Sophie CHERPEAU &#8211; Infirmi\u00e8re<\/li><li>Mme L\u00e9a DESNEUX &#8211; Ergoth\u00e9rapeute<\/li><li>Mme Oc\u00e9ane GUERRY &#8211; Assistante Sociale<\/li><li>Mme Pauline CHEVE &#8211; Di\u00e9t\u00e9ticienne<\/li><li>M. Mohammed MOUZOURI &#8211; Attach\u00e9 de Recherche Clinique<\/li><li>Mme Sabina DESCHATRETTES &#8211; Secr\u00e9taire<\/li><\/ul><p><strong>Laboratoires de diagnostic mol\u00e9culaire<\/strong><\/p><p>Laboratoire de Biochimie et Biologie Mol\u00e9culaire :<\/p><ul><li>Pr Patrick VOURC\u2019H (R\u00e9f\u00e9rent National)<\/li><li>Pr H\u00e9l\u00e8ne BLASCO<\/li><li>Dr Charlotte VEYRAT-DUREBEX<\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4b02614e elementor-widget elementor-widget-accordion\" data-id=\"4b02614e\" data-element_type=\"widget\" data-widget_type=\"accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 15-07-2024 *\/\n.elementor-accordion{text-align:start}.elementor-accordion .elementor-accordion-item{border:1px solid #d5d8dc}.elementor-accordion .elementor-accordion-item+.elementor-accordion-item{border-top:none}.elementor-accordion .elementor-tab-title{margin:0;padding:15px 20px;font-weight:700;line-height:1;cursor:pointer;outline:none}.elementor-accordion .elementor-tab-title .elementor-accordion-icon{display:inline-block;width:1.5em}.elementor-accordion .elementor-tab-title .elementor-accordion-icon svg{width:1em;height:1em}.elementor-accordion .elementor-tab-title .elementor-accordion-icon.elementor-accordion-icon-right{float:right;text-align:right}.elementor-accordion .elementor-tab-title .elementor-accordion-icon.elementor-accordion-icon-left{float:left;text-align:left}.elementor-accordion .elementor-tab-title .elementor-accordion-icon .elementor-accordion-icon-closed{display:block}.elementor-accordion .elementor-tab-title .elementor-accordion-icon .elementor-accordion-icon-opened,.elementor-accordion .elementor-tab-title.elementor-active .elementor-accordion-icon-closed{display:none}.elementor-accordion .elementor-tab-title.elementor-active .elementor-accordion-icon-opened{display:block}.elementor-accordion .elementor-tab-content{display:none;padding:15px 20px;border-top:1px solid #d5d8dc}@media (max-width:767px){.elementor-accordion .elementor-tab-title{padding:12px 15px}.elementor-accordion .elementor-tab-title .elementor-accordion-icon{width:1.2em}.elementor-accordion .elementor-tab-content{padding:7px 15px}}.e-con-inner>.elementor-widget-accordion,.e-con>.elementor-widget-accordion{width:var(--container-widget-width);--flex-grow:var(--container-widget-flex-grow)}<\/style>\t\t<div class=\"elementor-accordion\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1251\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-1251\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Pour prendre rendez vous :<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1251\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-1251\"><ul><li><p><strong>H\u00f4pital Bretonneau &#8211; B\u00e2timent B3<\/strong><\/p><p>T\u00e9l : <span style=\"color: #ed1164\"><strong>02 47 47 37 24\u00a0<\/strong><\/span><\/p><\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-11e45ef5 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"11e45ef5\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2ba83cc\" data-id=\"2ba83cc\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-29db1117 elementor-widget elementor-widget-image\" data-id=\"29db1117\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"240\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/recherche-300x240-1.png\" class=\"attachment-medium size-medium wp-image-369\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">RECHERCHE<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-61237471 elementor-widget elementor-widget-toggle\" data-id=\"61237471\" data-element_type=\"widget\" data-widget_type=\"toggle.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-toggle\">\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1621\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-1621\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>Recherche<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-1621\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-1621\"><p>L\u2019\u00e9quipe de Tours d\u00e9veloppe depuis plus de 20 ans maintenant une activit\u00e9 de Recherche importante dans deux th\u00e9matiques essentiellement : l\u2019identification de facteurs g\u00e9n\u00e9tiques de susceptibilit\u00e9 et de biomarqueurs diagnostiques et pronostiques permettant un diagnostic plus pr\u00e9coce et une capacit\u00e9 de pr\u00e9dire l\u2019\u00e9volution de la SLA du patient analys\u00e9, puisqu\u2019il n\u2019y a pas de profil \u00e9volutif classique pour cette maladie. Cette recherche est possible gr\u00e2ce \u00e0 l\u2019appui de l\u2019unit\u00e9 Inserm U1253 \u00abImaging Brain and Neuropsychiatry \u00bb et plus sp\u00e9cifiquement sur l\u2018\u00e9quipe 3 \u00ab <strong>Vuln\u00e9rabilit\u00e9 Neuronale<\/strong>\u00bb.<\/p><p>Le centre de Tours est l\u2019un des centres du groupe europ\u00e9en ENCALS (European Network to cure ALS) qui coordonne plusieurs projets internationaux notamment sur les facteurs g\u00e9n\u00e9tiques et l\u2019identification de biomarqueurs et membre de la gouvernance du groupe TRICALS (<strong>Treatment Research Initiative to Cure ALS<\/strong>) <strong>dont l\u2019objectif est de gu\u00e9rir les patients atteints de la SLA<\/strong>.<\/p><p>Tours coordonne avec le centre de Limoges au sein de FILSLAN le projet international de g\u00e9n\u00e9tique \u00ab Mine \u00bb ; ce projet initi\u00e9 par l\u2019\u00e9quipe du Pr van den Berg d\u2019Utrecht ambitionne d\u2019identifier les facteurs g\u00e9n\u00e9tiques de la SLA ce qui ouvrira de nombreuses pistes th\u00e9rapeutiques.<\/p><p>Le centre de Tours a accueilli en 2019 le congres europ\u00e9en sur les maladies du motoneurones, l\u2019ENCALS.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1622\" class=\"elementor-tab-title\" data-tab=\"2\" role=\"button\" aria-controls=\"elementor-tab-content-1622\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>essais th\u00e9rapeutiques<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-1622\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"region\" aria-labelledby=\"elementor-tab-title-1622\"><p><strong>EN COURS DE RECRUTEMENT :<\/strong><\/p><ul><li><strong>AB19001<\/strong> : Efficacit\u00e9 et s\u00e9curit\u00e9 du MASITINIB par rapport au placebo dans le <br \/>traitement des patients atteints de SLA<ul><li>Phase : III<\/li><li>Mol\u00e9cule : MASITINIB (AB1010)<\/li><li>Promoteur : AB Sciences<br \/><strong>En savoir plus<\/strong> :\u00a0 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03127267\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT03127267<\/a><\/li><\/ul><\/li><\/ul><p><strong>RECRUTEMENT TERMINE ET EN COURS DE SUIVI<\/strong><\/p><ul><li><b>HIMALAYA ACT16970 <\/b>: Etude de phase II de l\u2019effet SAR443820 chez des patients atteints de Scl\u00e9rose Lat\u00e9rale Amyotrophique<ul><li>Phase : II<\/li><li>Mol\u00e9cule : SAR443820<\/li><li>Promoteur : SANOFI AVENTIS<br \/><strong>En savoir plus <\/strong>: <u><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05237284\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05237284<\/a><\/u><\/li><\/ul><\/li><\/ul><ul><li><b>TRIALS <\/b>: Traitement associant le RILUZOLE et l\u2019IFB-088 dans la scl\u00e9rose lat\u00e9rale amyotrophique bulbaire<ul><li>Phase : II<\/li><li>Mol\u00e9cule : IFB-088<\/li><li>Promoteur : INFLECTIS BIOSCIENCE<br \/><strong>En savoir plus<\/strong> : <u><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05508074\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05508074<\/a><\/u><\/li><\/ul><\/li><\/ul><ul><li><b>TUDCA-OLE <\/b>: \u00c9tude d&#8217;extension en ouvert pour \u00e9valuer la s\u00e9curit\u00e9, la tol\u00e9rabilit\u00e9 et\u00a0 l&#8217;efficacit\u00e9 \u00e0 long terme de l&#8217;acide tauroursod\u00e9soxycholique pour les patients atteints\u00a0 de SLA qui ont termin\u00e9 l&#8217;\u00e9tude TUDCA-ALS<ul><li>Mol\u00e9cule : ACIDE TAUROURSODESOXYCHOLIQUE<\/li><li>Promoteur : HUMANITAS MIRASOLE SPA<br \/><strong>En savoir plus<\/strong> : <u><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03800524\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT03800524<\/a><\/u><\/li><\/ul><\/li><\/ul><ul><li><b>PHOENIX_OLE : <\/b>Etude d\u2019extension de phase IIIb men\u00e9e en ouvert visant \u00e0 \u00e9valuer la s\u00e9curit\u00e9 et la tol\u00e9rance de l\u2019AMX0035 jusqu\u2019\u00e0 108 semaines chez des patients adultes\u00a0 atteints de scl\u00e9rose lat\u00e9rale amyotrophique (SLA) pr\u00e9c\u00e9demment inclus dans l\u2019\u00e9tude<ul><li>A35-004 (PHOENIX)<\/li><li>Phase : III<\/li><li>Mol\u00e9cule : AMX0035<\/li><li>Promoteur : AMYLYX<br \/><strong>En savoir plus <\/strong>: <u><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05021536\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05021536<\/a><\/u><\/li><\/ul><\/li><\/ul><ul><li><b>DAZALS\u00a0: <\/b>Etude de phase 2, multicentrique, randomis\u00e9e, en double aveugle, contr\u00f4l\u00e9e par placebo, \u00e9valuant la s\u00e9curit\u00e9 et l\u2019efficacit\u00e9 du CORT113176 (DAZUCORILANT) chez les patients atteints de scl\u00e9rose lat\u00e9rale amyotrophique<ul><li>Phase : II<\/li><li>Mol\u00e9cule : CORT113176<\/li><li>Promoteur : CORCEPT THERAPEUTICS<br \/><strong>En savoir plus<\/strong> : <u><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05407324\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05407324<\/a><\/u><\/li><\/ul><\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1623\" class=\"elementor-tab-title\" data-tab=\"3\" role=\"button\" aria-controls=\"elementor-tab-content-1623\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>ETUDES PHYSIOPATHOLOGIQUES<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-1623\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"region\" aria-labelledby=\"elementor-tab-title-1623\"><p><strong>EN COURS DE RECRUTEMENT :<\/strong><\/p><ul><li><p><strong>RNALS<\/strong> : Diagnostic salivaire de la SLA : une approche par l\u2019analyse des ARN codants et non codants<br \/><strong>En savoir plus<\/strong> : <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05928416\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05928416<\/a><\/p><\/li><\/ul><ul><li><strong>BIOSTAGING<\/strong> : Etude d\u2019une cohorte observationnelle analytique \u00e0 la fois r\u00e9trospective monocentrique et prospective multicentrique<br \/><strong>En savoir plus<\/strong> : <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04858555\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT04858555<\/a><\/li><\/ul><ul><li><strong>DIAGALS<\/strong> : Relation TDP-43 et Nrf-2 dans la SLA: une piste pour am\u00e9liorer le diagnostic et le pronostic de la maladie. Etude prospective, bi-centrique, non-randomis\u00e9e, en ouvert<\/li><\/ul><p><strong>RECRUTEMENT TERMINE ET EN COURS DE SUIVI :<\/strong><\/p><ul><li><b>PULSE <\/b>: \u00c9tude des facteurs pr\u00e9dictifs de l\u2019\u00e9volutivit\u00e9 de la scl\u00e9rose lat\u00e9rale amyotrophique<br \/><strong>En savoir plus <\/strong>: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02360891\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT02360891<\/a><\/li><\/ul><ul><li><strong>FILSLAN-NF<\/strong> : Apport du dosage des Neurofilaments pour le diagnostic de SLA dans les situations d\u2019impasse diagnostique apr\u00e8s \u00e9valuation en centre expert SLA<br \/><strong>En savoir plus <\/strong>: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05077696\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05077696<\/a><\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-52982fa3 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"52982fa3\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6149970b\" data-id=\"6149970b\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4581e3c elementor-view-stacked elementor-shape-circle elementor-widget elementor-widget-icon\" data-id=\"4581e3c\" data-element_type=\"widget\" data-widget_type=\"icon.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-icon-wrapper\">\n\t\t\t<div class=\"elementor-icon\">\n\t\t\t<i aria-hidden=\"true\" class=\"fas fa-book-reader\"><\/i>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-345d590a elementor-widget elementor-widget-toggle\" data-id=\"345d590a\" data-element_type=\"widget\" data-widget_type=\"toggle.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-toggle\">\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-8781\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-8781\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>PUBLICATIONS<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-8781\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-8781\"><h4>2023<\/h4><ul><li><u><b>A <\/b><\/u><u><b>randomized<\/b><\/u><u><b> double-<\/b><\/u><u><b>blind<\/b><\/u> <u><b>clinical<\/b><\/u><u><b> trial on <\/b><\/u><u><b>safety<\/b><\/u><u><b> and <\/b><\/u><u><b>efficacy<\/b><\/u><u><b> of <\/b><\/u><u><b>tauroursodeoxycholic<\/b><\/u> <u><b>acid<\/b><\/u><u><b> (TUDCA) as <\/b><\/u><u><b>add-on<\/b><\/u> <u><b>treatment<\/b><\/u><u><b> in patients <\/b><\/u><u><b>affected<\/b><\/u><u><b> by <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b> (ALS): the <\/b><\/u><u><b>statistical<\/b><\/u> <u><b>analysis<\/b><\/u><u><b> plan of TUDCA-ALS trial.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Lombardo FL, Spila Alegiani S, Mayer F, Cipriani M, Lo Giudice M, Ludolph AC, McDermott CJ, <b>Corcia<\/b><b> P<\/b>, Van Damme P, Van den Berg LH, Hardiman O, Nicolini G, Vanacore N, Dickie B, Albanese A, Puopolo M; TUDCA-ALS Study Group. Trials. 2023 Dec 5<\/p><ul><li><u><b>Genetic<\/b><\/u> <u><b>variability<\/b><\/u><u><b> in <\/b><\/u><u><b>sporadic<\/b><\/u> <u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Van Daele SH, Moisse M, van Vugt JJFA, Zwamborn RAJ, van der Spek R, van Rheenen W, Van Eijk K, Kenna K, <b>Corcia<\/b><b> P<\/b>, <b>Vourc&#8217;h<\/b><b> P<\/b>, Couratier P, Hardiman O, McLaughin R, Gotkine M, Drory V, Ticozzi N, Silani V, Ratti A, de Carvalho M, Mora Pardina JS, Povedano M, Andersen PM, Weber M, Ba\u015fak NA, Shaw C, Shaw PJ, Morrison KE, Landers JE, Glass JD, van Es MA, van den Berg LH, Al-Chalabi A, Veldink J, Van Damme P. Brain. 2023 Sep 1<\/p><ul><li><u><b>Diagnostic <\/b><\/u><u><b>delay<\/b><\/u><u><b> in <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Gwathmey KG, <b>Corcia<\/b><b> P<\/b>, McDermott CJ, Genge A, Sennf\u00e4lt S, de Carvalho M, Ingre C. Eur J Neurol. 2023 Sep<\/p><ul><li><u><b>COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, <b>Corcia<\/b><b> P<\/b>, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug<\/p><ul><li><u><b>Implication of Central Nervous System Barrier Impairment in Amyotrophic Lateral Sclerosis: Gender-Related Difference in Patients.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Alarcan<\/b><b> H, <\/b><b>Vourc&#8217;h<\/b><b> P, <\/b><b>Berton<\/b><b> L, Benz-De Bretagne I, <\/b><b>Piver<\/b><b> E, Andres CR, <\/b><b>Corcia<\/b><b> P, <\/b><b>Veyrat-Durebex<\/b><b> C, <\/b><b>Blasco<\/b><b> H. <\/b>Int J Mol Sci. 2023 Jul 7<\/p><ul><li><u><b>Evaluation of arterial blood gas parameters as prognostic markers in amyotrophic lateral sclerosis.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Alarcan<\/b><b> H, <\/b><b>Cotet<\/b><b> C, <\/b><b>L\u00e9pine<\/b><b> N, Morel J, <\/b><b>Vourc&#8217;h<\/b><b> P, Andres C, <\/b><b>Corcia<\/b><b> P, <\/b><b>Blasco<\/b><b> H. <\/b>Eur J Neurol. 2023 Jun<\/p><ul><li><u><b>The contribution of Neanderthal introgression and natural selection to neurodegenerative diseases.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Chen Z, Reynolds RH, Pardi\u00f1as AF, Gagliano Taliun SA, van Rheenen W, Lin K, Shatunov A, Gustavsson EK, Fogh I, Jones AR, Robberecht W, <b>Corcia<\/b><b> P<\/b>, Chi\u00f2 A, Shaw PJ, Morrison KE, Veldink JH, van den Berg LH, Shaw CE, Powell JF, Silani V, Hardy JA, Houlden H, Owen MJ, Turner MR, Ryten M, Al-Chalabi A. Neurobiol Dis. 2023 May<\/p><ul><li><u><b>Large-<\/b><\/u><u><b>scale<\/b><\/u><u><b> analyses of CAV1 and CAV2 <\/b><\/u><u><b>suggest<\/b><\/u> <u><b>their<\/b><\/u><u><b> expression <\/b><\/u><u><b>is<\/b><\/u> <u><b>higher<\/b><\/u><u><b> in post-mortem ALS <\/b><\/u><u><b>brain<\/b><\/u><u><b> tissue and affects <\/b><\/u><u><b>survival<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Adey BN, Cooper-Knock J, Al Khleifat A, Fogh I, van Damme P, <b>Corcia<\/b><b> P<\/b>, Couratier P, Hardiman O, McLaughlin R, Gotkine M, Drory V, Silani V, Ticozzi N, Veldink JH, van den Berg LH, de Carvalho M, Pinto S, Mora Pardina JS, Povedano Panades M, Andersen PM, Weber M, Ba\u015fak NA, Shaw CE, Shaw PJ, Morrison KE, Landers JE, Glass JD, <b>Vourc&#8217;h<\/b><b> P<\/b>, Dobson RJB, Breen G, Al-Chalabi A, Jones AR, Iacoangeli A. Front Cell Neurosci. 2023 Mar 2<\/p><ul><li><u><b>Comparison<\/b><\/u> <u><b>between<\/b><\/u><u><b> PFN1 and SOD1 mutations in <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P, Lejeune P, <\/b><b>Vourc&#8217;h<\/b><b> P, <\/b><b>Beltran<\/b><b> S, <\/b><b>Piegay<\/b><b> AS, <\/b><b>Blasco<\/b><b> H<\/b>, Meininger V. Eur J Neurol. 2023 Feb<\/p><ul><li><u><b>Cognitive impairment in ALS has been known since the nineteenth century.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P<\/b>, Couratier P. Neurol Sci. 2023 Feb<\/p><ul><li><u><b>Study of Ubiquitin Pathway Genes in a French Population with Amyotrophic Lateral Sclerosis: Focus on HECW1 Encoding the E3 Ligase NEDL1.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Haouari<\/b><b> S, Andres CR, <\/b><b>Lanznaster<\/b><b> D, <\/b><b>Marouillat<\/b><b> S, <\/b><b>Brulard<\/b><b> C, <\/b><b>Dangoumau<\/b><b> A, Ung D<\/b>, <b>Veyrat-Durebex<\/b><b> C, <\/b><b>Laumonnier<\/b><b> F, <\/b><b>Blasco<\/b><b> H, <\/b>Couratier P, <b>Corcia<\/b><b> P, <\/b><b>Vourc&#8217;h<\/b><b> P<\/b>; French ALS network FILSLAN. Int J Mol Sci. 2023 Jan 9<\/p><p><b>2022<\/b><\/p><ul><li><u><b>Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Al Khleifat A, Iacoangeli A, Jones AR, van Vugt JJFA, Moisse M, Shatunov A, Zwamborn RAJ, van der Spek RAA, Cooper-Knock J, Topp S, van Rheenen W, Kenna B, Van Eijk KR, Kenna K, Byrne R, L\u00f3pez V, Opie-Martin S, Vural A, Campos Y, Weber M, Smith B, Fogh I, Silani V, Morrison KE, Dobson R, van Es MA, McLaughlin RL, Vourc&#8217;h P, Chio A, <b>Corcia<\/b><b> P<\/b>, de Carvalho M, Gotkine M, Panades MP, Mora JS, Shaw PJ, Landers JE, Glass JD, Shaw CE, Basak N, Hardiman O, Robberecht W, Van Damme P, van den Berg LH, Veldink JH, Al-Chalabi A. Front Cell Neurosci. 2022 Dec 15<\/p><ul><li><u><b>Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Willemse SW, Roes KCB, Van Damme P, Hardiman O, Ingre C, Povedano M, Wray NR, Gijzen M, de Pagter MS, Demaegd KC, Janse AFC, Vink RG, Sleutjes BTHM, Chi\u00f2 A, <b>Corcia<\/b><b> P<\/b>, Reviers E, Al-Chalabi A, Kiernan MC, van den Berg LH, van Es MA, van Eijk RPA. Trials. 2022 Dec 5<\/p><ul><li><u><b>Clinical trials in pediatric ALS: a TRICALS feasibility study. <\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P<\/b> et al.\u00a0 Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov<\/p><ul><li><u><b>Inflammatory<\/b><\/u> <u><b>mediators<\/b><\/u><u><b>, <\/b><\/u><u><b>lipoproteins<\/b><\/u><u><b> and <\/b><\/u><u><b>apolipoproteins<\/b><\/u><u><b> in <\/b><\/u><u><b>early<\/b><\/u> <u><b>diagnosis<\/b><\/u><u><b> of <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Alarcan<\/b><b> H, Berthet M, <\/b><b>Suire<\/b><b> L, Colas C, Gonzalez L, Paget C, Benz-de Bretagne I, <\/b><b>Piver<\/b><b> E, <\/b><b>Vourc&#8217;h<\/b><b> P, Andres C, <\/b><b>Corcia<\/b><b> P, <\/b><b>Blasco<\/b><b> H.<\/b> SLAS Technol. 2022 Oct<\/p><ul><li><u><b>Tauroursodeoxycholic<\/b><\/u> <u><b>acid<\/b><\/u><u><b> in patients with <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>: The TUDCA-ALS trial <\/b><\/u><u><b>protocol<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Albanese A, Ludolph AC, McDermott CJ, <b>Corcia<\/b><b> P<\/b>, Van Damme P, Van den Berg LH, Hardiman O, Rinaldi G, Vanacore N, Dickie B; TUDCA-ALS Study Group. Front Neurol. 2022 Sep 27<\/p><ul><li><u><b>Metabolomics<\/b><\/u><u><b> and <\/b><\/u><u><b>lipidomics<\/b><\/u> <u><b>approaches<\/b><\/u><u><b> in <\/b><\/u><u><b>human<\/b><\/u> <u><b>tears<\/b><\/u><u><b>: A <\/b><\/u><u><b>systematic<\/b><\/u> <u><b>review<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Khanna<\/b><b> RK, <\/b><b>Catanese<\/b><b> S, <\/b><b>Emond<\/b><b> P, <\/b><b>Corcia<\/b><b> P, <\/b><b>Blasco<\/b><b> H, <\/b><b>Pisella<\/b><b> PJ<\/b>. Surv Ophthalmol. 2022 Jul-Aug<\/p><ul><li><u><b>Metabolic<\/b><\/u><u><b> Profile and <\/b><\/u><u><b>Pathological<\/b><\/u> <u><b>Alterations<\/b><\/u><u><b> in the Muscle of Patients with <\/b><\/u><u><b>Early<\/b><\/u><u><b>-Stage <\/b><\/u><u><b>Amyotrophic<\/b><\/u> <u><b>Lateral<\/b><\/u> <u><b>Sclerosis<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Lanznaster<\/b><b> D, Bruno C, <\/b><b>Bourgeais<\/b><b> J, <\/b><b>Emond<\/b><b> P, <\/b><b>Zemmoura<\/b><b> I, Lef\u00e8vre A, <\/b><b>Reynier<\/b><b> P, <\/b><b>Eymieux<\/b><b> S, Blanchard E, <\/b><b>Vourc&#8217;h<\/b><b> P, Andres CR, <\/b><b>Bakkouche<\/b><b> SE, <\/b><b>Herault<\/b><b> O, <\/b><b>Favard<\/b><b> L, <\/b><b>Corcia<\/b><b> P, <\/b><b>Blasco<\/b><b> H. <\/b>Biomedicines. 2022 Jun 2<\/p><ul><li><u><b>TAR DNA-binding <\/b><\/u><u><b>protein<\/b><\/u><u><b> of 43 kDa (TDP-43) and <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b> (ALS): a <\/b><\/u><u><b>promising<\/b><\/u> <u><b>therapeutic<\/b><\/u> <u><b>target<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Ojaimi<\/b><b> YA, <\/b><b>Dangoumau<\/b><b> A, <\/b><b>Alarcan<\/b><b> H, Hergesheimer R, <\/b><b>Vourc&#8217;h<\/b><b> P, <\/b><b>Corcia<\/b><b> P, <\/b><b>Lanznaster<\/b><b> D, <\/b><b>Blasco<\/b><b> H. <\/b>Expert Opin Ther Targets. 2022 Jun<\/p><ul><li><u><b>Taking<\/b><\/u> <u><b>Advantages<\/b><\/u><u><b> of Blood-Brain or Spinal <\/b><\/u><u><b>Cord<\/b><\/u> <u><b>Barrier<\/b><\/u> <u><b>Alterations<\/b><\/u><u><b> or <\/b><\/u><u><b>Restoring<\/b><\/u> <u><b>Them<\/b><\/u><u><b> to <\/b><\/u><u><b>Optimize<\/b><\/u> <u><b>Therapy<\/b><\/u><u><b> in ALS?<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Alarcan<\/b><b> H, Al <\/b><b>Ojaimi<\/b><b> Y, <\/b><b>Lanznaster<\/b><b> D, <\/b><b>Escoffre<\/b><b> JM, <\/b><b>Corcia<\/b><b> P, <\/b><b>Vourc&#8217;h<\/b><b> P, Andres CR, <\/b><b>Veyrat-Durebex<\/b><b> C, <\/b><b>Blasco<\/b><b> H. <\/b>J Pers Med. 2022 Jun 29<\/p><ul><li><u><b>Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P<\/b> et al. Nat Genet. 2022 Mar<\/p><ul><li><u><b>The <\/b><\/u><u><b>Roles<\/b><\/u><u><b> of NEDD4 <\/b><\/u><u><b>Subfamily<\/b><\/u><u><b> of HECT E3 <\/b><\/u><u><b>Ubiquitin<\/b><\/u><u><b> Ligases in <\/b><\/u><u><b>Neurodevelopment<\/b><\/u><u><b> and <\/b><\/u><u><b>Neurodegeneration<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Haouari<\/b><b> S, <\/b><b>Vourc&#8217;h<\/b><b> P, Jeanne M, <\/b><b>Marouillat<\/b><b> S, <\/b><b>Veyrat-Durebex<\/b><b> C, <\/b><b>Lanznaster<\/b><b> D, <\/b><b>Laumonnier<\/b><b> F, <\/b><b>Corcia<\/b><b> P, <\/b><b>Blasco<\/b><b> H, Andres CR. <\/b>Int J Mol Sci. 2022 Mar 31<\/p><ul><li><u><b>Genome-wide<\/b><\/u> <u><b>study<\/b><\/u><u><b> of DNA <\/b><\/u><u><b>methylation<\/b><\/u><u><b> shows <\/b><\/u><u><b>alterations<\/b><\/u><u><b> in <\/b><\/u><u><b>metabolic<\/b><\/u><u><b>, <\/b><\/u><u><b>inflammatory<\/b><\/u><u><b>, and <\/b><\/u><u><b>cholesterol<\/b><\/u> <u><b>pathways<\/b><\/u><u><b> in ALS.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P<\/b> et al. Sci Transl Med. 2022 Feb 23<\/p><ul><li><u><b>Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Al Khleifat A, Iacoangeli A, van Vugt JJFA, Bowles H, Moisse M, Zwamborn RAJ, van der Spek RAA, Shatunov A, Cooper-Knock J, Topp S, Byrne R, Gellera C, L\u00f3pez V, Jones AR, Opie-Martin S, Vural A, Campos Y, van Rheenen W, Kenna B, Van Eijk KR, Kenna K, Weber M, Smith B, Fogh I, Silani V, Morrison KE, Dobson R, van Es MA, McLaughlin RL, Vourc&#8217;h P, Chio A, <b>Corcia<\/b><b> P<\/b>, de Carvalho M, Gotkine M, Panades MP, Mora JS, Shaw PJ, Landers JE, Glass JD, Shaw CE, Basak N, Hardiman O, Robberecht W, Van Damme P, van den Berg LH, Veldink JH, Al-Chalabi A. NPJ Genom Med. 2022 Jan 28<\/p><ul><li><u><b>The <\/b><\/u><u><b>hypometabolic<\/b><\/u><u><b> state: a good predictor of a better prognosis in amyotrophic lateral sclerosis.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Cattaneo M, Jesus P, Lizio A, Fayemendy P, Guanziroli N, Corradi E, Sansone V, Leocani L, Filippi M, Riva N, <b>Corcia<\/b><b> P<\/b>, Couratier P, Lunetta C. J Neurol Neurosurg Psychiatry. 2022 Jan<\/p><p><b>2021<\/b><\/p><ul><li><u><b>Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <\/b><\/u><b>Corcia<\/b><b> P<\/b> et al . Nat Genet. 2021 Dec<\/li><li><u><b>Towards<\/b><\/u> <u><b>personalized<\/b><\/u> <u><b>medicine<\/b><\/u><u><b> for <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">Cassereau J, <b>Corcia<\/b><b> P<\/b>, Reynier P. Trends Endocrinol Metab. 2021 Nov<\/p><ul><li><u><b>Split-hand and split-<\/b><\/u><u><b>limb<\/b><\/u> <u><b>phenomena<\/b><\/u><u><b> in <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>: <\/b><\/u><u><b>pathophysiology<\/b><\/u><u><b>, <\/b><\/u><u><b>electrophysiology<\/b><\/u><u><b> and <\/b><\/u><u><b>clinical<\/b><\/u><u><b> manifestations.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P<\/b>, Bede P, Pradat PF, Couratier P, Vucic S, de Carvalho M. J Neurol Neurosurg Psychiatry. 2021 Oct<\/p><ul><li><u><b>Impact of a <\/b><\/u><u><b>frequent<\/b><\/u> <u><b>nearsplice<\/b><\/u><u><b> SOD1 variant in <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>: <\/b><\/u><u><b>optimising<\/b><\/u><u><b> SOD1 <\/b><\/u><u><b>genetic<\/b><\/u><u><b> screening for <\/b><\/u><u><b>gene<\/b><\/u> <u><b>therapy<\/b><\/u> <u><b>opportunities<\/b><\/u>.<\/li><\/ul><p style=\"padding-left: 40px;\">Muratet F, Teyssou E, Chiot A, Boill\u00e9e S, Lobsiger CS, Bohl D, Gyorgy B, Guegan J, Marie Y, Amador MDM, Salachas F, Meininger V, Bernard E, Antoine JC, Camdessanch\u00e9 JP, Camu W, Cazeneuve C, Fauret-Amsellem AL, Leguern E, Mouzat K, Guissart C, Lumbroso S, <b>Corcia<\/b><b> P, <\/b><b>Vourc&#8217;h<\/b><b> P<\/b>, Grapperon AM, Attarian S, Verschueren A, Seilhean D, Millecamps S. J Neurol Neurosurg Psychiatry. 2021 Sep<\/p><ul><li><u><b>Familial <\/b><\/u><u><b>clustering<\/b><\/u><u><b> of <\/b><\/u><u><b>primary<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b> and <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>: <\/b><\/u><u><b>Supplementary<\/b><\/u> <u><b>evidence<\/b><\/u><u><b> for a continuum.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P<\/b>, Lunetta C, Couratier P, Vourc&#8217;h P, Gromicho M, Desnuelle C, Soriani MH, Pinto S, de Carvalho M. Eur J Neurol. 2021 Aug<\/p><ul><li><u><b>Frontotemporal<\/b><\/u> <u><b>Pathology<\/b><\/u><u><b> in <\/b><\/u><u><b>Motor<\/b><\/u> <u><b>Neuron<\/b><\/u> <u><b>Disease<\/b><\/u> <u><b>Phenotypes<\/b><\/u><u><b>: Insights <\/b><\/u><u><b>From<\/b><\/u> <u><b>Neuroimaging<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\">McKenna MC, <b>Corcia<\/b><b> P<\/b>, Couratier P, Siah WF, Pradat PF, Bede P. Front Neurol. 2021 Aug 16<\/p><ul><li><u><b>TDP43 <\/b><\/u><u><b>aggregates<\/b><\/u><u><b>: the &#8216;<\/b><\/u><u><b>Schr\u00f6dinger&#8217;s<\/b><\/u><u><b> cat&#8217; in <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Lanznaster<\/b><b> D, Hergesheimer R, <\/b><b>Vourc&#8217;h<\/b><b> P, <\/b><b>Corcia<\/b><b> P, <\/b><b>Blasco<\/b><b> H.<\/b> Nat Rev Neurosci. 2021 Aug<\/p><ul><li><u><b>Effect<\/b><\/u><u><b> of familial <\/b><\/u><u><b>clustering<\/b><\/u><u><b> in the <\/b><\/u><u><b>genetic<\/b><\/u><u><b> screening of 235 French ALS <\/b><\/u><u><b>families<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P<\/b>, <b>Camu<\/b><b> W<\/b>, Brulard C, Marouillat S, Couratier P, Camdessanch\u00e9 JP, Cintas P, Verschueren A, Soriani MH, Desnuelle C, Fleury MC, Guy N, Cassereau J, Viader F, Pittion-Vouyovitch S, Danel V, Kolev I, Le Masson G, Beltran S, Salachas F, Bernard E, Pradat PF, <b>Blasco<\/b><b> H<\/b>, Lanznaster D, Hergesheimer R, <b>Laumonnier<\/b><b> F, Andres CR<\/b>, Meininger V, <b>Vourc&#8217;h<\/b><b> P<\/b>. J Neurol Neurosurg Psychiatry. 2021 May<\/p><ul><li><u><b>Some<\/b><\/u><u><b> CSF <\/b><\/u><u><b>Kynurenine<\/b><\/u> <u><b>Pathway<\/b><\/u> <u><b>Intermediates<\/b><\/u><u><b> Associated with <\/b><\/u><u><b>Disease<\/b><\/u><u><b> Evolution in <\/b><\/u><u><b>Amyotrophic<\/b><\/u> <u><b>Lateral<\/b><\/u> <u><b>Sclerosis<\/b><\/u><u><b>.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Alarcan<\/b><b> H, <\/b><b>Chaumond<\/b><b> R, <\/b><b>Emond<\/b><b> P, Benz-De Bretagne I, Lef\u00e8vre A,<\/b> <b>Bakkouche<\/b><b> SE<\/b>, <b>Veyrat-Durebex<\/b><b> C, <\/b><b>Vourc&#8217;h<\/b><b> P, Andres C,<\/b> <b>Corcia<\/b><b> P<\/b>, <b>Blasco<\/b><b> H<\/b>. Biomolecules. 2021 May 5<\/p><ul><li><u><b>The Effect of SMN Gene Dosage on ALS Risk and Disease Severity. <\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Corcia<\/b><b> P<\/b> et al. Ann Neurol. 2021 Apr<\/p><ul><li><u><b>Dysregulations<\/b><\/u><u><b> of Expression of <\/b><\/u><u><b>Genes<\/b><\/u><u><b> of the <\/b><\/u><u><b>Ubiquitin<\/b><\/u><u><b>\/SUMO <\/b><\/u><u><b>Pathways<\/b><\/u><u><b> in an In Vitro Model of <\/b><\/u><u><b>Amyotrophic<\/b><\/u> <u><b>Lateral<\/b><\/u> <u><b>Sclerosis<\/b><\/u> <u><b>Combining<\/b><\/u> <u><b>Oxidative<\/b><\/u><u><b> Stress and SOD1 Gene Mutation.<\/b><\/u><\/li><\/ul><p style=\"padding-left: 40px;\"><b>Dangoumau<\/b><b> A, <\/b><b>Marouillat<\/b><b> S, Coelho R, Wurmser F, <\/b><b>Brulard<\/b><b> C, <\/b><b>Haouari<\/b><b> S, <\/b><b>Laumonnier<\/b><b> F, <\/b><b>Corcia<\/b><b> P, Andres CR, <\/b><b>Blasco<\/b><b> H, <\/b><b>Vourc&#8217;h<\/b><b> P. <\/b>Int J Mol Sci. 2021 Feb 11<\/p><p><b>2020<\/b><\/p><ul><li><u><b>Conservative iron chelation for neurodegenerative diseases such as Parkinson&#8217;s disease and amyotrophic lateral sclerosis. <\/b><\/u>Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC; FAIRPARK-II and FAIRALS-II studygroups. Collaborateurs <b>Philippe <\/b><b>Corcia<\/b><b>, Stephane Beltran. <\/b>J Neural Transm (Vienna). 2020 Jan.<\/li><\/ul><p><b>2019<\/b><\/p><ul><li><u><b>TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis.<\/b><\/u> <b>Lanznaster<\/b><b> D<\/b>, Bourgeais J, Bruno C, Hergesheimer RC, Thepault RA, <b>Vourc&#8217;h<\/b><b> P,<\/b> <b>Corcia<\/b><b> P<\/b>, <b>Andres CR, <\/b><b>Herault<\/b><b> O, <\/b><b>Blasco<\/b><b> H. <\/b>Cells. 2019 Dec.<\/li><li><u><b>Phenotypes<\/b><\/u><u><b> and <\/b><\/u><u><b>malignancy<\/b><\/u> <u><b>risk<\/b><\/u><u><b> of <\/b><\/u><u><b>different<\/b><\/u><u><b> FUS mutations in <\/b><\/u><u><b>genetic<\/b><\/u> <u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u>. Naumann M, Peikert K, G\u00fcnther R, van der Kooi AJ, Aronica E, H\u00fcbers A, Danel V, <b>Corcia<\/b><b> P<\/b>, Pan-Montojo F, Cirak S, Haliloglu G, Ludolph AC, Goswami A, Andersen PM, Prudlo J, Wegner F, Van Damme P, Weishaupt JH, Hermann A. Ann Clin Transl Neurol. 2019 Dec.<\/li><li><u><b>A <\/b><\/u><u><b>role<\/b><\/u><u><b> for <\/b><\/u><u><b>SUMOylation<\/b><\/u><u><b> in the Formation and Cellular <\/b><\/u><u><b>Localization<\/b><\/u><u><b> of TDP-43 <\/b><\/u><u><b>Aggregates<\/b><\/u><u><b> in <\/b><\/u><u><b>Amyotrophic<\/b><\/u> <u><b>Lateral<\/b><\/u> <u><b>Sclerosis<\/b><\/u><u><b>. <\/b><\/u>Maurel C, Chami AA, Th\u00e9pault RA, Marouillat S, <b>Blasco<\/b><b> H, <\/b><b>Corcia<\/b><b> P, Andres CR, <\/b><b>Vourc&#8217;h<\/b><b> P.<\/b> Mol Neurobiol. 2019 Nov .<\/li><li><u><b>Grey Matter 150th anniversary of Charcot&#8217;s description of amyotrophic lateral sclerosis. <\/b><\/u><b>Corcia<\/b><b> P<\/b>, Meininger V. Brain. 2019 Oct.<\/li><li><u><b>Hearing<\/b><\/u> <u><b>loss<\/b><\/u><u><b> in <\/b><\/u><u><b>inherited<\/b><\/u> <u><b>peripheral<\/b><\/u><u><b> neuropathies: <\/b><\/u><u><b>Molecular<\/b><\/u> <u><b>diagnosis<\/b><\/u><u><b> by NGS in a French <\/b><\/u><u><b>series<\/b><\/u>. Lerat J, Magdelaine C, Roux AF, Darnaud L, Beauvais-Dzugan H, Naud S, Richard L, Derouault P, Ghorab K, Magy L, Vallat JM, Cintas P, Bieth E, Arne-Bes MC, Goizet C, Espil-Taris C, Journel H, Toutain A, Urtizberea JA, Boespflug-Tanguy O, Laffargue F, <b>Corcia<\/b><b> P<\/b>, Pasquier L, Fradin M, Napuri S, Ciron J, Boulesteix JM, Sturtz F, Lia AS. Mol Genet Genomic Med. 2019 Sep<\/li><li><u><b>Implanted<\/b><\/u> <u><b>Phrenic<\/b><\/u><u><b> Stimulation Impairs Local <\/b><\/u><u><b>Diaphragm<\/b><\/u> <u><b>Myofiber<\/b><\/u> <u><b>Reinnervation<\/b><\/u><u><b> in <\/b><\/u><u><b>Amyotrophic<\/b><\/u> <u><b>Lateral<\/b><\/u> <u><b>Sclerosis<\/b><\/u><u><b>. <\/b><\/u>Guimar\u00e3es-Costa R, Ni\u00e9rat MC, Rivals I, Mor\u00e9lot-Panzini C, Romero NB, Menegaux F, Salachas F, Gonzalez-Bermejo J, Similowski T, Bruneteau G; RespiStimALS team. Collaborateur <b>Philippe <\/b><b>Corcia<\/b>. Am J Respir Crit Care Med. 2019 Nov<\/li><li><u><b>Residential<\/b><\/u> <u><b>exposure<\/b><\/u><u><b> to ultra high <\/b><\/u><u><b>frequency<\/b><\/u> <u><b>electromagnetic<\/b><\/u> <u><b>fields<\/b><\/u> <u><b>emitted<\/b><\/u><u><b> by Global System for Mobile (GSM) <\/b><\/u><u><b>antennas<\/b><\/u><u><b> and <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b> incidence: A <\/b><\/u><u><b>geo-epidemiological<\/b><\/u><u><b> population-<\/b><\/u><u><b>based<\/b><\/u> <u><b>study<\/b><\/u>. Luna J, Leleu JP, Preux PM, <b>Corcia<\/b><b> P<\/b>, Couratier P, Marin B, Boumediene F; Fralim Consortium.Environ Res. 2019 Sep<\/li><\/ul><ul><li><u><b>A phase III trial of <\/b><\/u><u><b>tirasemtiv<\/b><\/u><u><b> as a <\/b><\/u><u><b>potential<\/b><\/u> <u><b>treatment<\/b><\/u><u><b> for <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>. <\/b><\/u>Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA; VITALITY-ALS Study Group. Collaborateur <b>Philippe <\/b><b>Corcia<\/b>. Amyotroph Lateral Scler Frontotemporal Degener. 2019<\/li><li><u><b>ROCK-ALS: Protocol for a <\/b><\/u><u><b>Randomized<\/b><\/u><u><b>, Placebo-<\/b><\/u><u><b>Controlled<\/b><\/u><u><b>, Double-Blind Phase <\/b><\/u><u><b>IIa<\/b><\/u><u><b> Trial of <\/b><\/u><u><b>Safety<\/b><\/u><u><b>, <\/b><\/u><u><b>Tolerability<\/b><\/u><u><b> and <\/b><\/u><u><b>Efficacy<\/b><\/u><u><b> of the Rho Kinase (ROCK) <\/b><\/u><u><b>Inhibitor<\/b><\/u> <u><b>Fasudil<\/b><\/u><u><b> in <\/b><\/u><u><b>Amyotrophic<\/b><\/u> <u><b>Lateral<\/b><\/u> <u><b>Sclerosis<\/b><\/u><u><b>. <\/b><\/u>Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, G\u00fcnther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC; ROCK-ALS Investigators. Collaborateur <b>Philippe <\/b><b>Corcia<\/b>. Front Neurol. 2019 Mar 27<\/li><li><u><b>Ferritin<\/b><\/u><u><b> and LDL-<\/b><\/u><u><b>cholesterol<\/b><\/u><u><b> as <\/b><\/u><u><b>biomarkers<\/b><\/u><u><b> of fat-free mass <\/b><\/u><u><b>loss<\/b><\/u><u><b> in ALS<\/b><\/u>. J\u00e9sus P, <b>Blasco<\/b><b> H, Patin F, <\/b><b>Bakkouche<\/b><b> SE<\/b>, <b>Beltran<\/b><b> S<\/b>, <b>Andr\u00e9s CR<\/b>, <b>Vourc&#8217;h<\/b><b> P, Maillot F<\/b>, <b>Corcia<\/b><b> P<\/b>. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug<\/li><li><u><b>The <\/b><\/u><u><b>debated<\/b><\/u> <u><b>toxic<\/b><\/u> <u><b>role<\/b><\/u><u><b> of <\/b><\/u><u><b>aggregated<\/b><\/u><u><b> TDP-43 in <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u><u><b>: a <\/b><\/u><u><b>resolution<\/b><\/u><u><b> in <\/b><\/u><u><b>sight<\/b><\/u><u><b>? <\/b><\/u>Hergesheimer RC, Chami AA, de Assis DR, <b>Vourc&#8217;h<\/b><b> P, Andres CR, <\/b><b>Corcia<\/b><b> P, <\/b><b>Lanznaster<\/b><b> D, <\/b><b>Blasco<\/b><b> H<\/b>. Brain. 2019 May 1<\/li><li><u><b>Efficacy<\/b><\/u><u><b> and <\/b><\/u><u><b>Safety<\/b><\/u><u><b> of <\/b><\/u><u><b>Octagam<\/b><\/u><u><b>\u00ae in Patients With <\/b><\/u><u><b>Chronic<\/b><\/u> <u><b>Inflammatory<\/b><\/u> <u><b>Demyelinating<\/b><\/u> <u><b>Polyneuropathy<\/b><\/u>. Belmokhtar C, Lozeron P, Adams D, Franques J, Lacour A, Godet E, Bataille M, Dubourg O, Angibaud G, Delmont E, Bouhour F, <b>Corcia<\/b><b> P<\/b>, Pouget J. Neurol Ther. 2019 Jun<\/li><li><u><b>Revised<\/b><\/u> <u><b>Airlie<\/b><\/u><u><b> House consensus guidelines for design and <\/b><\/u><u><b>implementation<\/b><\/u><u><b> of ALS <\/b><\/u><u><b>clinical<\/b><\/u><u><b> trials. <\/b><\/u>Van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, <b>Corcia<\/b><b> P<\/b>, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H; Airlie House ALS Clinical Trials Guidelines Group. Neurology. 2019 Apr 2<\/li><li><u><b>A <\/b><\/u><u><b>ferroptosis-based<\/b><\/u><u><b> panel of <\/b><\/u><u><b>prognostic<\/b><\/u> <u><b>biomarkers<\/b><\/u><u><b> for <\/b><\/u><u><b>Amyotrophic<\/b><\/u> <u><b>Lateral<\/b><\/u> <u><b>Sclerosis<\/b><\/u><u><b>. <\/b><\/u>Devos D, Moreau C, Kyheng M, Gar\u00e7on G, Rolland AS, Blasco H, Gel\u00e9 P, Timoth\u00e9e Lenglet T, Veyrat-Durebex C, <b>Corcia<\/b><b> P<\/b>, Dutheil M, Bede P, Jeromin A, Oeckl P, Otto M, Meninger V, Danel-Brunaud V, Devedjian JC, Duce JA, Pradat PF. Sci Rep. 2019 Feb<\/li><li><u><b>The <\/b><\/u><u><b>Relevancy<\/b><\/u><u><b> of Data <\/b><\/u><u><b>Regarding<\/b><\/u><u><b> the <\/b><\/u><u><b>Metabolism<\/b><\/u><u><b> of <\/b><\/u><u><b>Iron<\/b><\/u><u><b> to Our <\/b><\/u><u><b>Understanding<\/b><\/u><u><b> of <\/b><\/u><u><b>Deregulated<\/b><\/u> <u><b>Mechanisms<\/b><\/u><u><b> in ALS; <\/b><\/u><u><b>Hypotheses<\/b><\/u><u><b> and <\/b><\/u><u><b>Pitfalls<\/b><\/u><u><b>.<\/b><\/u> Petillon C, Hergesheimer R, Puy H, <b>Corcia<\/b><b> P<\/b>, <b>Vourc&#8217;h<\/b><b> P, Andres C<\/b>, Karim Z, Blasco H. Front Neurosci. 2019 Jan<\/li><li><u><b>Metabo-lipidomics<\/b><\/u><u><b> of <\/b><\/u><u><b>Fibroblasts<\/b><\/u><u><b> and Mitochondrial-<\/b><\/u><u><b>Endoplasmic<\/b><\/u> <u><b>Reticulum<\/b><\/u> <u><b>Extracts<\/b><\/u> <u><b>from<\/b><\/u><u><b> ALS Patients Shows <\/b><\/u><u><b>Alterations<\/b><\/u><u><b> in Purine, Pyrimidine, <\/b><\/u><u><b>Energetic<\/b><\/u><u><b>, and <\/b><\/u><u><b>Phospholipid<\/b><\/u> <u><b>Metabolisms<\/b><\/u><u><b>.<\/b><\/u> <b>Veyrat-Durebex<\/b><b> C<\/b>, Bris C, Codron P, Bocca C, Chupin S, <b>Corcia<\/b><b> P<\/b>, <b>Vourc&#8217;h<\/b><b> P<\/b>, Hergesheimer R, Cassereau J, Funalot B, <b>Andres CR<\/b>, Lenaers G, Couratier P, Reynier P, <b>Blasco<\/b><b> H<\/b>. Mol Neurobiol. 2019 Aug<\/li><li><u><b>Human<\/b><\/u> <u><b>diaphragm<\/b><\/u> <u><b>atrophy<\/b><\/u><u><b> in <\/b><\/u><u><b>amyotrophic<\/b><\/u> <u><b>lateral<\/b><\/u> <u><b>sclerosis<\/b><\/u> <u><b>is<\/b><\/u><u><b> not <\/b><\/u><u><b>predicted<\/b><\/u><u><b> by routine <\/b><\/u><u><b>respiratory<\/b><\/u> <u><b>measures<\/b><\/u><u><b>. <\/b><\/u>Guimar\u00e3es-Costa R, Similowski T, Rivals I, Mor\u00e9lot-Panzini C, Nierat MC, Bui MT, Akbar D, Straus C, Romero NB, Michel PP, Menegaux F, Salachas F, Gonzalez-Bermejo J, Bruneteau G; RespiStimALS team; contributors to the RespiStimALS study were: Collaborateur <b>Philippe <\/b><b>Corcia<\/b>. Eur Respir J. 2019 Feb<\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-39955632 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"39955632\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-78798438\" data-id=\"78798438\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3c965fc elementor-widget elementor-widget-image\" data-id=\"3c965fc\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"263\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/enseignement-300x263-1.png\" class=\"attachment-medium size-medium wp-image-365\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">ENSEIGNEMENT<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2542ff elementor-widget elementor-widget-toggle\" data-id=\"2542ff\" data-element_type=\"widget\" data-widget_type=\"toggle.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-toggle\">\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-2441\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-2441\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>Enseignement<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-2441\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-2441\"><h4><strong>Formation Internes du 3<sup>\u00e8me<\/sup> cycle<\/strong><\/h4><ul><li>Formations Sp\u00e9cialis\u00e9es Transversales (FST)<\/li><\/ul><h4><strong>Les Formations Post-Universitaires\u00a0<\/strong><\/h4><ul><li><b>DU Maladies du Motoneurone (D\u00e8s septembre 2024)<\/b><\/li><li><b>MASTER Sciences, Technologies, Sant\u00e9 MENTION Biologie &#8211; Sant\u00e9 PARCOURS Cognition, Neurosciences et Psychologie <\/b><a href=\"http:\/\/www.univ-tours.fr\" target=\"_blank\" rel=\"noopener\"><u>www.univ-tours.fr<\/u><\/a><\/li><\/ul><h4><strong>Autres Formations<\/strong><\/h4><ul><li><strong>Formation E-Learning sur la SLA<\/strong> (destin\u00e9e aux professionnels de sant\u00e9 intervenants au domicile et aux aidants)<br \/><a href=\"https:\/\/portail-sla.fr\/formation-e-learning-sur-la-sla\/\" target=\"_blank\" rel=\"noopener\">https:\/\/portail-sla.fr\/formation-e-learning-sur-la-sla\/<\/a><\/li><li><strong>E-Learning Echelle Fonctionnelle de la SLA<br \/><\/strong><a href=\"https:\/\/www.encals.eu\/outcome-measures\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.encals.eu\/outcome-measures\/<\/a><\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-5c039d85 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"5c039d85\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1f276d99\" data-id=\"1f276d99\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7e9db6da elementor-widget elementor-widget-image\" data-id=\"7e9db6da\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"212\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/outils-300x212-1.png\" class=\"attachment-medium size-medium wp-image-367\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">OUTILS<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-146b7f23 elementor-widget elementor-widget-toggle\" data-id=\"146b7f23\" data-element_type=\"widget\" data-widget_type=\"toggle.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-toggle\">\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-3421\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-3421\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>Outils<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-3421\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-3421\"><p><strong>PNDS (Protocole National de Diagnostic et de Soins)<\/strong><\/p><blockquote><p>D\u00e9finition HAS :<\/p><p><em><strong>L\u2019objectif d\u2019un PNDS<\/strong> est d\u2019expliciter aux professionnels concern\u00e9s la prise en charge diagnostique et th\u00e9rapeutique optimale actuelle et le parcours de soins d\u2019un patient atteint d\u2019une maladie rare donn\u00e9e. Il a pour but d\u2019optimiser et d\u2019harmoniser la prise en charge et le suivi de la maladie rare sur l\u2019ensemble du territoire.<\/em><\/p><p><em>Le PNDS peut servir de r\u00e9f\u00e9rence au m\u00e9decin traitant (m\u00e9decin d\u00e9sign\u00e9 par le patient aupr\u00e8s de la Caisse d\u2019Assurance Maladie) en concertation avec le m\u00e9decin sp\u00e9cialiste notamment au moment d\u2019\u00e9tablir le protocole de soins conjointement avec le m\u00e9decin conseil et le patient, dans le cas d&#8217;une demande d&#8217;exon\u00e9ration du ticket mod\u00e9rateur au titre d&#8217;une affection hors liste.<\/em><\/p><\/blockquote><ul><li><strong>SCL\u00c9ROSE LAT\u00c9RALE AMYOTROPHIQUE<\/strong> (novembre 2015)<br \/><a href=\"https:\/\/www.has-sante.fr\/jcms\/c_2573383\/fr\/sclerose-laterale-amyotrophique\" target=\"_blank\" rel=\"noopener\">https:\/\/www.has-sante.fr\/jcms\/c_2573383\/fr\/sclerose-laterale-amyotrophique<\/a><\/li><li><strong>AMYOTROPHIE BULBO-SPINALE LI\u00c9E \u00c0 L\u2019X OU MALADIE DE KENNEDY<\/strong> (juin 2017)<br \/><a href=\"https:\/\/www.has-sante.fr\/jcms\/c_2776017\/fr\/amyotrophie-bulbo-spinale-liee-a-l-x-ou-maladie-de-kennedy\" target=\"_blank\" rel=\"noopener\">https:\/\/www.has-sante.fr\/jcms\/c_2776017\/fr\/amyotrophie-bulbo-spinale-liee-a-l-x-ou-maladie-de-kennedy<\/a><\/li><\/ul><p><strong>Recommandations de Bonnes Pratiques<\/strong><\/p><ul><li><strong>LES DIRECTIVES ANTICIP\u00c9ES<\/strong> (janvier 2017)<br \/><a href=\"https:\/\/www.has-sante.fr\/jcms\/c_2722363\/fr\/pour-tous-comment-rediger-vos-directives-anticipees\" target=\"_blank\" rel=\"noopener\">https:\/\/www.has-sante.fr\/jcms\/c_2722363\/fr\/pour-tous-comment-rediger-vos-directives-anticipees<\/a><\/li><li><strong>LA PERSONNE DE CONFIANCE<\/strong><br \/><a href=\"https:\/\/solidarites-sante.gouv.fr\/systeme-de-sante-et-medico-social\/parcours-de-sante-vos-droits\/modeles-et-documents\/guide-usagers-votre-sante-vos-droits\/article\/fiche-9-la-personne-de-confiance-215415\" target=\"_blank\" rel=\"noopener\">https:\/\/solidarites-sante.gouv.fr\/systeme-de-sante-et-medico-social\/parcours-de-sante-vos-droits\/modeles-et-documents\/guide-usagers-votre-sante-vos-droits\/article\/fiche-9-la-personne-de-confiance-215415<\/a><\/li><li><strong>COMMENT METTRE EN \u0152UVRE UNE S\u00c9DATION PROFONDE ET CONTINUE MAINTENUE JUSQU\u2019AU D\u00c9C\u00c8S ?<\/strong> (mars 2018)<br \/><a href=\"https:\/\/www.has-sante.fr\/jcms\/c_2832000\/fr\/comment-mettre-en-oeuvre-une-sedation-profonde-et-continue-maintenue-jusqu-au-deces\" target=\"_blank\" rel=\"noopener\">https:\/\/www.has-sante.fr\/jcms\/c_2832000\/fr\/comment-mettre-en-oeuvre-une-sedation-profonde-et-continue-maintenue-jusqu-au-deces<\/a><\/li><li><strong>Prise en charge des personnes atteintes de scl\u00e9rose lat\u00e9rale amyotrophique<\/strong> (f\u00e9vrier 2006)<br \/><a href=\"https:\/\/www.has-sante.fr\/jcms\/c_409014\/fr\/prise-en-charge-des-personnes-atteintes-de-sclerose-laterale-amyotrophique\" target=\"_blank\" rel=\"noopener\">https:\/\/www.has-sante.fr\/jcms\/c_409014\/fr\/prise-en-charge-des-personnes-atteintes-de-sclerose-laterale-amyotrophique<\/a><\/li><\/ul><p><strong>Carte d&#8217;urgence<\/strong><\/p><ul><li><strong>SCL\u00c9ROSE LAT\u00c9RALE AMYOTROPHIQUE<\/strong><br \/><a href=\"https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Emergency.php?lng=FR\" target=\"_blank\" rel=\"noopener\">https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Emergency.php?lng=FR<\/a><\/li><\/ul><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2b17714e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2b17714e\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3e22f0c6\" data-id=\"3e22f0c6\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-62fe566c elementor-widget elementor-widget-image\" data-id=\"62fe566c\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"192\" src=\"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-content\/uploads\/sites\/15\/2023\/02\/liens-300x192-1.png\" class=\"attachment-medium size-medium wp-image-370\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">LIENS<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1efaeb57 elementor-widget elementor-widget-toggle\" data-id=\"1efaeb57\" data-element_type=\"widget\" data-widget_type=\"toggle.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-toggle\">\n\t\t\t\t\t\t\t<div class=\"elementor-toggle-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-5191\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-5191\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon elementor-toggle-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-closed\"><i class=\"fas fa-caret-right\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-toggle-icon-opened\"><i class=\"elementor-toggle-icon-opened fas fa-caret-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-toggle-title\" tabindex=\"0\"><span style=\"text-transform: uppercase\"><strong>Liens<\/strong><\/span><\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div id=\"elementor-tab-content-5191\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-5191\"><ul><li><b>Fili\u00e8re de sant\u00e9<br \/><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-5229\" src=\"https:\/\/www.chu-tours.fr\/wp-content\/uploads\/2020\/01\/logo-filslan.png\" alt=\"\" width=\"160\" height=\"106\" \/><br \/><\/b><ul><li><strong>FILSAN Fili\u00e8re de Sant\u00e9 Maladies Rares Scl\u00e9rose Lat\u00e9rale Amyotrophique et Maladies Neurones Moteur <\/strong>: <a href=\"https:\/\/portail-sla.fr\/\" target=\"_blank\" rel=\"noopener\">https:\/\/portail-sla.fr\/<\/a><\/li><\/ul><\/li><\/ul><ul><li><b>Soci\u00e9t\u00e9s savantes<\/b><ul><li><strong>Groupe Fran\u00e7ais d\u2019Etude des Maladies du Motoneurone (GFEMM)<\/strong><\/li><li><strong>Soci\u00e9t\u00e9 Fran\u00e7aise de Neurologie<\/strong><br \/><a href=\"https:\/\/www.sf-neuro.org\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sf-neuro.org\/<\/a><\/li><li><strong>ENCALS European Network to Cure ALS (R\u00e9seau Europ\u00e9en SLA)<\/strong><br \/><a href=\"https:\/\/www.encals.eu\/about-encals\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.encals.eu\/about-encals\/<\/a><\/li><li><strong>Soci\u00e9t\u00e9 des Neurosciences<\/strong> <br \/><a href=\"https:\/\/www.neurosciences.asso.fr\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.neurosciences.asso.fr\/<\/a><\/li><\/ul><\/li><\/ul><ul><li><b>Associations de patients<\/b><ul><li>Pour plus d\u2019informations sur les associations de patients atteints de la SLA et les autres associations patients :<br \/><a href=\"https:\/\/portail-sla.fr\/associations-3\/\" target=\"_blank\" rel=\"noopener\">https:\/\/portail-sla.fr\/associations-3\/<\/a><\/li><\/ul><\/li><li><strong>R\u00e9seau Neuro centre<\/strong><\/li><\/ul><p style=\"padding-left: 40px;\">Le R\u00e9seau Neuro Centre est consacr\u00e9 \u00e0 l\u2019accompagnement des patients atteints de Scl\u00e9rose En Plaques (SEP) ou de Scl\u00e9rose Lat\u00e9rale Amyotrophique (SLA) en r\u00e9gion Centre Val de Loire :<\/p><p style=\"padding-left: 40px;\"><a href=\"https:\/\/www.reseauneurocentre.fr\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.reseauneurocentre.fr\/<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Face \u00e0 l\u2019\u00e9pid\u00e9mie de coronavirus qui touche la France, les \u00e9quipes de l\u2019ARSLA restent op\u00e9rationnelles pour prot\u00e9ger les malades, les aidants et les informer ! L\u2019\u00e9pid\u00e9mie de COVID-19 actuellement en cours en France impose aux personnes fragiles d\u2019\u00eatre particuli\u00e8rement vigilantes et de prendre de fortes pr\u00e9cautions pour \u00e9viter tout risque de contamination. L&#8217;ARSLA reste mobilis\u00e9e [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_robots_primary_cat":"","_seopress_titles_title":"Centre de R\u00e9f\u00e9rence Constitutif sur la Scl\u00e9rose Lat\u00e9rale Amyotrophique et autres Maladies Rares du Neurone Moteur","_seopress_titles_desc":"Le Centre de r\u00e9f\u00e9rence constitutif est compos\u00e9 d\u2019une \u00e9quipe multidisciplinaire sp\u00e9cialis\u00e9e dans la prise en charge de la Scl\u00e9rose Lat\u00e9rale Amyotrophique  et des autres Maladies Rares du Neurone Moteur.","_seopress_robots_index":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2026-05-08 04:13:23","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-json\/wp\/v2\/pages\/471"}],"collection":[{"href":"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-json\/wp\/v2\/comments?post=471"}],"version-history":[{"count":16,"href":"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-json\/wp\/v2\/pages\/471\/revisions"}],"predecessor-version":[{"id":1999,"href":"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-json\/wp\/v2\/pages\/471\/revisions\/1999"}],"wp:attachment":[{"href":"https:\/\/www.chu-tours.fr\/pemr-cvl\/wp-json\/wp\/v2\/media?parent=471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}